Company Description
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia.
Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.
The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024.
Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Spyridon Papapetropoulos |
Contact Details
Address: 14 Milliston Road, Box 195 Millis, Massachusetts 02054 United States | |
| Phone | 339 240 6066 |
| Website | neuphoriatx.com |
Stock Details
| Ticker Symbol | NEUP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001191070 |
| CUSIP Number | 64136E102 |
| ISIN Number | US64136E1029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Interim Chief Executive Officer and Executive Director |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
| Adrian Hinton BEC, F.C.A. | Financial Controller |
| Rajeev Chandra B.Com., C.A., M.B.A. | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2026 | SCHEDULE 13G | Filing |
| Sep 18, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 18, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 18, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 18, 2026 | 10-K | Annual Report |
| Jul 28, 2026 | SCHEDULE 13G/A | Filing |
| Jul 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 24, 2026 | 8-K | Current Report |
| May 26, 2026 | 8-K | Current Report |
| May 15, 2026 | 10-Q | Quarterly Report |